Issue link: http://cp.revolio.com/i/924515
Abby's Magazine - Volume 6 Issue 1 | Page 35 can have dangerous side effects. Avandia is linked to 43 percent increased risk of heart a ack and 64 percent higher risk of cardio- vascular death, compared with other treatments. Instead, type 2 diabetes is best controlled by restoring your insulin and lep n sensi vi es. This is done by elimina ng grains and sugars— especially fructose—from your diet, ge ng plenty of healthy fats, exercising, and sleeping well. Further details on this will be provided below, in the treatment sec on. As noted earlier, recent research published in the Journal of Clinical Endocrinology & Metabolism confirms what Dr. Ron Rosedale has stated for the last two decades, which is that insulin treatment can provoke otherwise reversible type 2 diabetes to progress into type 1 insulin deficient and therefore insulin-dependent diabetes. The study found that giving gene cally engineered recombinant insulin to type 2 diabe cs with certain gene c suscep bility can trigger their bodies to produce an bodies that destroy their insulin producing cells (pancrea c islet cells). You may not realize that all human insulin, the type typically used, is GMO or gene cally modified which might be responsible for this autoimmune reac on. Basically, it triggers an autoimmune disease response, producing a condi on in which you have both type 1 and type 2 diabetes simultaneously. The average me of type 1 diabetes onset was 7.7 months. One study par cipant developed type 1 diabetes in just over one month! According to the authors, acute deteriora on of blood glucose control a er administering insulin is a warning sign of this problema c side effect. According to this study, the genes predisposing you to this autoimmune-type response to insulin are: • Type 1 diabetes high risk HLA class II (IDDM1), thought to play a role in about half of all type 1 diabetes cases. • VNTR genotype (IDDM2), which is believed to predispose you to type 2 diabetes. This is yet another way conven onal diabe c treatment pushes diabe cs into premature death... Research published last year revealed that trea ng type 2 diabetes with insulin more than doubled pa ents' risk of all-cause mortality. It also leads to: Another study published in Diabetologia in May of this year, found that diabe c cancer pa ents also have a significantly elevated risk of death. Diabe c pa ents using insulin at the me of their cancer diagnosis had a four mes higher mortality rate one year a er cancer diagnosis, compared to non-diabe c pa ents, or those who did not use insulin to control their diabetes. While this was an observa onal study, which means it cannot establish causality, it is worth no ng nonetheless. Dr. Rosedale has also said: "All of these increased rates of chronic diseases caused by taking insulin may be because it is doing exactly the opposite of what has been shown in many studies to reduce cancer, total mortality, and extend lifespan; reducing insulin. In fact, T2 diabetes is o en considered to be a model of accelerated aging because of the high insulin. In other words, trea ng diabe cs by overly raising insulin, either with drugs or insulin itself, is only further accelera ng their aging, associated chronic diseases, and death, and should be considered malprac ce." Warning #2: Beware of Future Diabetic Vaccines As noted by GreenMedInfo.com, these findings also raise serious warnings against diabe c vaccines: "[T]here are a number of trials underway to produce vaccines containing insulin intended to induce a 'tolerogenic immune response' and therefore ameliorate autoimmune type 1 diabetes. Clearly, however, their findings run contrary to this expecta on, revealing that it is possible that introducing exogenous forms of insulin may s mulate the opposite reac on and induced autoimmunity against the hormone, or the cells in the pancreas responsible for producing it." It also raises ques ons about the safety and effec veness Twice as many myocardial infarc ons 1.4 me more strokes 2.1 me more neuropathy 1.4 mes more cancer 1.7 me more major adverse cardiac events 3.5 mes more renal complica ons 1.2 mes more eye complica ons 2.2 mes more deaths